Abrupt Discontinuation: Risks and Considerations Some individuals might consider stopping their GLP-1 medication abruptly, but this approach carries significant risks
El ensayo SELECT demostr que semaglutide reduce MACE en un 20% en personas con sobrepeso u obesidad y enfermedad cardiovascular aterosclertica establecida, pero sin diabetes tipo 2, separando los beneficios cardiovasculares de los efectos hipoglucemiantes
Patients who attained SVR with interferon or interferon-ribavirin, much higher in infections with genotypes 2 and 3, would have been excluded from genotyping.34,40 However, the first two hypotheses could also be applied to genotype 1a and 4 infections, also associated with IDU, while the third hypothesis would have involved so few patients in our series that its relevance would be negligible
2 Table 1 Results of Head to Head Comparisons among Short-, Long-, and Prolonged-Acting Glucagon-Like Peptide 1 Analogs Values are expressed as meanSD
The article calls that distinction crucial for both safety and value, and says pricing depends on pharmacy licensing, raw material sourcing, and regulatory compliance
Dont miss this super-informative and engaging episode of Be HEALTHistic